With current blockbuster brands facing generic competition, Datamonitor forecasts the antidepressant market to decline at a compound annual growth rate of -2.0% (20082018). However, an antidepressant with a novel mechanism of action has huge commercial potential and the most promising candidate to date is Servier and Novartis's melatonin agonist and serotonin antagonist Valdoxan (agomelatine).
Reasons to Purchase
Quantify the current (2008) and future (2009-2018) size of the antidepressant drug class market.
Assess the impact of recent and anticipated events (patent expiries and new product launches) on the antidepressant drug class market.
Understand the country-specific impact of key events in the antidepressant drug class market during the forecast period 2009 to 2018.
(0 items)
